149 related articles for article (PubMed ID: 22607579)
1. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
[TBL] [Abstract][Full Text] [Related]
2. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
Boyce M; Warrington S
Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
[TBL] [Abstract][Full Text] [Related]
3. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
Boyce M; Warrington S; Black J
Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
[TBL] [Abstract][Full Text] [Related]
4. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
[TBL] [Abstract][Full Text] [Related]
5. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
Sørdal Ø; Waldum H; Nordrum IS; Boyce M; Bergh K; Munkvold B; Qvigstad G
Helicobacter; 2013 Dec; 18(6):397-405. PubMed ID: 23865485
[TBL] [Abstract][Full Text] [Related]
6. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
7. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial of the effect of a gastrin/CCK
Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
[TBL] [Abstract][Full Text] [Related]
9. Randomized Controlled Trial of the Gastrin/CCK
Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
[TBL] [Abstract][Full Text] [Related]
10. Effects of tablet and effervescent formulations of ranitidine 75 mg and cimetidine 200 mg on gastric acidity and oesophageal acid exposure in healthy humans.
Bruley des Varannes S; Duquesnoy C; Mamet JP; Slama A; Galmiche JP; Scarpignato C
Aliment Pharmacol Ther; 1998 Nov; 12(11):1155-61. PubMed ID: 9845405
[TBL] [Abstract][Full Text] [Related]
11. Commentary: netazepide for gastric acid suppression--another kid on the block?
Metz DC
Aliment Pharmacol Ther; 2012 Aug; 36(3):294-5. PubMed ID: 22747455
[No Abstract] [Full Text] [Related]
12. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole.
Hurlimann S; Abbühl B; Inauen W; Halter F
Aliment Pharmacol Ther; 1994 Apr; 8(2):193-201. PubMed ID: 8038351
[TBL] [Abstract][Full Text] [Related]
13. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
14. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Kakuda TN; Falcon RW
Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
[TBL] [Abstract][Full Text] [Related]
15. Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022.
Kitano M; Norlén P; Ding XQ; Nakamura S; Håkanson R
Br J Pharmacol; 2000 Jun; 130(3):699-705. PubMed ID: 10821801
[TBL] [Abstract][Full Text] [Related]
16. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH.
Khoury RM; Katz PO; Hammod R; Castell DO
Aliment Pharmacol Ther; 1999 May; 13(5):675-8. PubMed ID: 10233192
[TBL] [Abstract][Full Text] [Related]
17. The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.
Webb DL; Rudholm-Feldreich T; Gillberg L; Halim MA; Theodorsson E; Sanger GJ; Campbell CA; Boyce M; Näslund E; Hellström PM
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jan; 386(1):41-9. PubMed ID: 23179899
[TBL] [Abstract][Full Text] [Related]
18. Nocturnal intragastric acidity after over-the-counter doses of famotidine, ranitidine or placebo.
Grimley CE; Cottrell J; Mann SG; Stauffer L; Nwokolo CU
Aliment Pharmacol Ther; 1997 Oct; 11(5):881-5. PubMed ID: 9354196
[TBL] [Abstract][Full Text] [Related]
19. The effects of low doses of ranitidine on intragastric acidity in healthy men.
Wyeth JW; Pounder RE; Sercombe JC; Snell CC
Aliment Pharmacol Ther; 1998 Mar; 12(3):255-61. PubMed ID: 9570260
[TBL] [Abstract][Full Text] [Related]
20. Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula.
Takemoto Y; Yuki H; Nishida A; Ito H; Kobayashi-Uchida A; Takinami Y; Akuzawa S; Ohta M; Satoh M; Semple G; Miyata K
Arzneimittelforschung; 1998 Apr; 48(4):403-7. PubMed ID: 9608884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
